These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 17920757

  • 1. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
    Ogawa H, Ikegame K, Kaida K, Yoshihara S, Fujioka T, Taniguchi Y, Tamaki H, Inoue T, Hasei H, Iiboshi Y, Tazuke Y, Kawakami M, Kim EH, Soma T, Inoue T, Kawase I.
    Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
    [Abstract] [Full Text] [Related]

  • 2. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H, Ikegame K, Yoshihara S, Kawakami M, Fujioka T, Masuda T, Taniguchi Y, Hasei H, Kaida K, Inoue T, Kim EH, Kawase I.
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [Abstract] [Full Text] [Related]

  • 3. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
    Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
    [Abstract] [Full Text] [Related]

  • 4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
    Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J.
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
    [Abstract] [Full Text] [Related]

  • 5. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
    Sabry W, Le Blanc R, Labbé AC, Sauvageau G, Couban S, Kiss T, Busque L, Cohen S, Lachance S, Roy DC, Roy J.
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
    [Abstract] [Full Text] [Related]

  • 6. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.
    Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR.
    Blood; 1998 Oct 01; 92(7):2303-14. PubMed ID: 9746768
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D, O'Toole K, Keller J, Connaghan DG, Heffner LT, Hillyer CD, Rodey GE, Winton EF, Maher RM, Fitzsimmons WE, Wingard JR.
    Biol Blood Marrow Transplant; 1997 Apr 01; 3(1):25-33. PubMed ID: 9209738
    [Abstract] [Full Text] [Related]

  • 11. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Varaldo R, Bacigalupo A.
    Biol Blood Marrow Transplant; 2013 Jan 01; 19(1):117-22. PubMed ID: 22940057
    [Abstract] [Full Text] [Related]

  • 12. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
    Topolsky D, Crilley P, Styler MJ, Bulova S, Brodsky I, Marks DI.
    Bone Marrow Transplant; 1996 Apr 01; 17(4):549-54. PubMed ID: 8722353
    [Abstract] [Full Text] [Related]

  • 13. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis.
    Yamada MF, Miyamura K, Fujiwara T, Kohata K, Okitsu Y, Ohguchi H, Yamamoto J, Yokoyama H, Tomiya Y, Ishizawa K, Kameoka J, Harigae H.
    Transplant Proc; 2008 Dec 01; 40(10):3637-42. PubMed ID: 19100456
    [Abstract] [Full Text] [Related]

  • 14. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, Gallagher G, Kerr H, Kuruvilla J, Lee SJ, Moore J, Nevill T, Popradi G, Roy J, Schultz KR, Szwajcer D, Toze C, Foley R, Cell Therapy Transplant Canada.
    Lancet Haematol; 2020 Feb 01; 7(2):e100-e111. PubMed ID: 31958417
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A, Ratanatharathorn V.
    Bone Marrow Transplant; 1997 Jun 01; 19(12):1233-8. PubMed ID: 9208118
    [Abstract] [Full Text] [Related]

  • 16. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F, Ostronoff M, Souto-Maior AP, Domingues M, Sucupira A, Manso DA, de Lima AK, Monteiro PG, Florêncio R, Calixto R.
    Clin Transplant; 2009 Jun 01; 23(1):33-8. PubMed ID: 18727660
    [Abstract] [Full Text] [Related]

  • 17. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
    van Besien K, Artz A, Champlin RE, Guarneri D, Bishop MR, Chen J, Gergis U, Shore T, Liu H, Rondon G, Mayer SA, Srour SA, Stock W, Ciurea SO.
    Blood Adv; 2019 Jun 25; 3(12):1858-1867. PubMed ID: 31217161
    [Abstract] [Full Text] [Related]

  • 18. [A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow].
    Chen H, Ji S, Wang H.
    Zhonghua Nei Ke Za Zhi; 2001 Nov 25; 40(11):760-3. PubMed ID: 11930684
    [Abstract] [Full Text] [Related]

  • 19. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.
    Biol Blood Marrow Transplant; 2004 Apr 25; 10(4):246-58. PubMed ID: 15077223
    [Abstract] [Full Text] [Related]

  • 20. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA, Kim JH, Jeon YW, Yoon JH, Shin SH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Kim HJ.
    Biol Blood Marrow Transplant; 2015 Jan 25; 21(1):119-29. PubMed ID: 25300871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.